Sen. Metzenbaum's orphan drug survey
Ohio Democrat sends second round of letters July 16 to firms that developed non-"blockbuster" drugs. He asked Immunex to estimate Leukine's U.S. patient population and total annual sales in 1991 or 1992. He asked Somerset about the patient population, price and sales of Eldepryl, Syntex about Cytovene, Enzon about Adagen and Genzyme about Ceredase. He sent similar letters July 10 to eight firms that market or hope to market human growth hormone, aerosolized pentamidine and erythropoietin ("The Pink Sheet" July 15, p. 6). Metzenbaum's interest in sales information in both questionnaires suggests he is considering legislation to place a sales cap on drugs granted orphan market exclusivity.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth